Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 7/20 | 0.55 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605171 | 0.89 | ABL1 (0.60) | ABL1ROCK2ROCK1KMT2AMEN1 | |
| SCHEMBL3593888 | 0.85 | MEN1 (0.63) | ABL1ROCK2ROCK1KMT2AMEN1 | |
| SCHEMBL3612358 | 0.83 | AOC3 (0.57) | ABL1WNT3AROCK2ROCK1KMT2A | |
| SCHEMBL3607745 | 0.82 | ROCK2 (0.56) | ABL1ROCK2ROCK1ALDH1A1HSD17B10 | |
| SCHEMBL8647952 | 0.80 | ATP4A (0.54) | RAB9ANPC1 | |
| SCHEMBL3607652 | 0.77 | KDM4E (0.44) | ABL1KMT2AMEN1ALDH1A1ALOX15 | |
| SCHEMBL3607108 | 0.76 | ABL1 (0.49) | ABL1KMT2AMEN1ALDH1A1ALOX15 | |
| SCHEMBL3607773 | 0.76 | KMT2A (0.68) | ABL1KMT2AMEN1ALDH1A1ALOX15 | |
| SCHEMBL3609158 | 0.75 | MEN1 (0.52) | ABL1KMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL3602005 | 0.75 | KMT2A (0.43) | ABL1ROCK2ROCK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | ABL1 4507/4885WNT3A 4075/4885ROCK2 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.